CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the closing of its previously announced public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consisted of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share.
Cowen and Company and Stifel acted as joint book-running managers for the offering. JMP Securities acted as lead manager and Oppenheimer & Co. acted as co-manager for the offering.
The offering was made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on October 1, 2014. A prospectus supplement has been filed with the SEC and forms a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone (631) 274-2806 or fax (631) 254-7140; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA, 94104, by telephone at (415) 364-2720 or by email to email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.